A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

The World Health Organization (WHO) has renewed attention on the importance of laboratory biosafety and biosecurity after the death of a worker at a plague research institute in Siberia, Russia. This comes even after Russian authorities confirm that no laboratory accident or confirmed plague infection.

In a Disease Outbreak News update published on October 10, the WHO stated it had not identified evidence of ongoing transmission of pneumonic plague linked to the incident. However, the cause of the worker's fatal pneumonia remains unexplained, leaving several emergency public health questions unanswered.

A 28-year-old lab technician of the Irkutsk Anti-Plague Research Institute who was hospitalised with severe pneumonia on September 29 and died on October 2.

Initial media reports suspected possible pneumonic plague following occupational exposure, but Russian authorities reported that tests had not detected plague or other dangerous pathogens.

WHO's Inquiry

Also read: Plague Treatable, CDC Monitoring US Arrivals From Russia After Worker’s Death, Says Director Erica Schwartz

According to updates provided by Russian authorities, more than 5,500 laboratory tests were conducted as part of the investigation. No high-threat pathogens were detected among high-risk contacts. Additionally, the contacts reportedly displayed no alarming symptoms.

Russia also told the WHO that two independent investigations found no laboratory biosafety or biosecurity incidents at the institute. The authorities classified the death as pneumonia of "undetermined origin" rather than plague.

However, the WHO has highlighted the fact that it has not received information about the confirmed cause of the fatal illness.

In its assessment, the agency stated, "A key uncertainty for this event is the absence of a confirmed diagnosis in the deceased laboratory worker."

The WHO added that the occupational setting remained relevant because the worker was employed at an institution that handled high-risk pathogens. “A laboratory-associated exposure therefore cannot be fully excluded at this stage,” the report said.

This does not establish that an accident occurred. Rather, it points towards the limits of the available evidence while the cause of death remains unresolved.

WHO Reiterates Laboratory Safety Rules

Also read: Russia Denies Second Plague Case As WHO Seeks Answers On Lab Death; Trump Says It’s Not A Bioweapon

The WHO's advice focuses on preventing occupational exposure to hazardous biological agents and reducing the risk of accidental leaks.

The agency emphasised that laboratories handling dangerous pathogens should maintain robust biosafety, biosecurity and infection prevention and control practices. These precautions apply routinely, regardless of whether a particular incident has been confirmed.

The WHO specifically clarified that its recommendation was precautionary and did not imply that a laboratory-related infection or incident had been confirmed yet.

Biosafety involves practices and equipment designed to prevent accidental exposure to infectious pathogens, while biosecurity focuses on preventing their loss, theft, misuse or unauthorised release.

Plague Outbreak Risk

The WHO said it had found no evidence of ongoing transmission associated with the incident. Russian authorities reported no recent plague cases in the Irkutsk region and said medical monitoring of contacts had been completed.

However, the absence of a confirmed diagnosis means the exact cause of the worker's death remains unknown, keeping loose ends open. The WHO said additional clinical, epidemiological and laboratory information would help strengthen its assessment.

Pneumonic plague, the form that initially prompted concern, affects the lungs and can spread between people through infectious respiratory droplets. It can be fatal without prompt treatment, although antibiotics can be effective when administered early.

Veteran actor Sharmila Tagore recently revisited her lung cancer diagnosis after she appeared on Soha Ali Khan's podcast All About Her with Saba Ali Khan. While Saba opened up about her brain tumour, they also discussed Sharmila's lung cancer which was diagnosed at stage zero.

The 81-year-old veteran actor insisted on undergoing surgery despite being diagnosed at stage zero lung cancer. She said that many believed that the procedure might not be necessary. Soha revealed that doctors confirmed that the tissue was malignant during surgery and were able to remove it completely.

Sharmila Tagore did not need chemotherapy after the surgery, according to Soha. In a chat with Nayandeep Rakshit, Soha shared that her mother did not need chemotherapy. "With my mother, she was one of the very few people to be diagnosed with lung cancer at stage zero. No chemotherapy, nothing. It was cut out of her, and she is, touchwood, fine," she said.

The actor's case brings up the question of whether surgery at the earliest stage of lung cancer can prevent the disease from progressing.

What Is Stage Zero Lung Cancer?

Stage zero is the earliest stage of non-small cell lung cancer, also called carcinoma in situ. At this stage, abnormal or cancerous cells are confined to the innermost lining of the airways and have not invaded deeper lung tissue or spread to lymph nodes or distant organs.

Unlike more advanced lung cancers, stage zero disease is often treatable with local treatment alone. However, it can be difficult to detect because it may not cause noticeable symptoms.

Also read: PET-CT in Colon Cancer: When Can It Help?

Can Surgery Stop Lung Cancer From Progressing?

In terms of progression, surgery can often help stage zero lung cancer, provided the abnormal tissue is completely removed and the diagnosis confirms that it has not become invasive.

The objective is to remove the affected tissue before the cancerous cells penetrate deeper into the lung. Depending on the lesion's size and location, surgeons may perform a wedge resection or segmentectomy, removing a small portion of the lung.

For patients whose cancer is confined to the airway lining, chemotherapy or radiation is generally not required after successful surgery, just like in Tagore's case.

Treatment decisions, however, depend on the final pathology report and individual clinical findings.

Also read: Left Delhi To Escape Air Pollution? Why Health Effects May Linger For A Long Time

Stage Zero Lung Cancer Is Difficult To Detect

Lung cancer is frequently diagnosed after it has progressed because early disease may produce fewer or no symptoms. Persistent cough, chest pain and breathlessness are not reliable early warning signs of stage zero disease.

Low-dose CT screening can help detect lung abnormalities before symptoms develop, especially among people at high risk, like certain long-term smokers.

However, screening recommendations depend on age and smoking history, and not every lung abnormality detected on a scan is cancer.

Even though complete removal of stage zero lung cancer can offer an excellent chance of cure, it does not eliminate every future risk.

Patients may need follow-up imaging and clinical assessments to monitor for recurrence or a new primary lung cancer. The risk varies depending on the original tumour, the type of treatment and individual factors.

Flu activity is rising unusually early in parts of the US, UK and Japan, while COVID-19 cases are also increasing in the UK. Health experts are urging eligible people to get vaccinated ahead of winter, when respiratory infections can add to pressure on hospitals.

According to Nature, flu tests are returning positive at unusually high rates for early fall on the US West Coast and in the UK. In Japan, outbreaks in August and early September forced some schools to close as students returned from summer break.

“It would be an incredibly early season” for the US if cases on the West Coast continue rising at their current pace, Scott Hensley, a virologist at the University of Pennsylvania, told Nature. US flu activity typically peaks in December and January.

H1N1 Dominates Flu Cases In The US

Also read: ‘American Covid’ Strain Drives 50% Surge in UK Hospital Admissions: XFG Symptoms to Know

H1N1 accounted for 96% of US flu cases tested for type in the week ending September 26. H3N2 accounted for nearly all the remaining cases, while no influenza B was detected, Nature reported, citing federal data.

The Centers for Disease Control and Prevention (CDC) classified the 2025–2026 US flu season as moderately severe, with more than 32 million cases, 390,000 hospitalizations and up to 81,000 deaths. Cases rose in November and peaked in December.

This season, flu activity began rising in August and September in western states, including California, Washington, Alaska and Hawaii.

“We’re looking at an early flu season this year,” James Watt, deputy director of infectious diseases at the California Department of Public Health, said at an October 6 briefing, according to the San Francisco Chronicle.

Danielle Zerr, an infectious diseases specialist at Seattle Children’s, told The Washington Post that the early spread was concerning because many people had yet to be vaccinated.

“The way flu is circulating now, you wanted that vaccine in you two weeks ago, if not even a little before that,” she said.

UK Reports Flu And COVID-19

Read More: XFG COVID Variant: What India Should Watch As Cases Rise In UK And France

In the UK, around 6.5% of flu tests were positive in the week reported by the UK Health Security Agency (UKHSA), up from 5% the previous week. This compares with 3.3% at the same point last year.The early rise has raised concerns that flu could add to pressure on the National Health Service (NHS), which has already experienced a busy summer. University students returning to campuses may also be contributing to the spread.

COVID-19 activity has increased as well. Reported infections rose from 1,374 in August to 4,589 in September, the highest monthly total since October last year, according to figures cited in reports. However, officials said levels of both infections remained within the expected range.

Frankie Swords, national medical director at NHS England, warned of early signs of winter pressure on hospitals. Around two in every 100,000 people in England were being hospitalized with flu, while overall hospital capacity was approximately 95% occupied in September.

Swords urged eligible people to get vaccinated early, warning that pressure could increase as temperatures fall.

Since the start of September, around 3.9 million people in the UK had received a flu vaccine, while approximately 730,000 had received an autumn COVID-19 vaccine.

France is also reporting a rise in COVID-19 cases as the government prepares to launch its autumn COVID and flu vaccination campaign on October 13.

Flu Symptoms You Should Know

Flu often begins suddenly, causing fever, chills, body aches and extreme fatigue.

Common symptoms include:

• Fever and chills
• Body aches
• Extreme fatigue
• Headache
• Sore throat
• Runny or stuffy nose
• Cough

Children may also experience vomiting and diarrhea. Flu symptoms can overlap with those of other respiratory infections, so testing may be needed to confirm the cause.

Do Flu Vaccines Protect Against All Circulating Strains?

Seasonal flu vaccines are designed to protect against selected influenza strains, including H1N1, H3N2 and influenza B viruses.

However, influenza viruses can undergo genetic changes known as antigenic drift, which may reduce vaccine effectiveness against circulating strains.

Flu and COVID-19 vaccines target different viruses. A flu shot does not protect against COVID-19, so eligible people may need separate vaccinations to reduce their risk of severe illness from both infections.